Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Application
Filed:
August 17, 2007
Publication date:
January 8, 2009
Applicant:
BIOGEN IDEC INC.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams
Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
Type:
Grant
Filed:
July 10, 2000
Date of Patent:
November 18, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
September 16, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams
Abstract: Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
Type:
Grant
Filed:
July 25, 2001
Date of Patent:
September 9, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: Isolated nucleic acids and proteins that are overexpressed in human cancers, and antibodies that specifically bind the proteins, which are useful diagnostic and therapeutic targets.
Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Type:
Application
Filed:
August 17, 2007
Publication date:
September 4, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Type:
Application
Filed:
August 17, 2007
Publication date:
September 4, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Type:
Application
Filed:
August 17, 2007
Publication date:
September 4, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Grant
Filed:
October 26, 2006
Date of Patent:
August 26, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
August 19, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams
Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
Type:
Application
Filed:
August 17, 2007
Publication date:
August 14, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Type:
Application
Filed:
August 17, 2007
Publication date:
July 17, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
Abstract: Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.
Type:
Grant
Filed:
July 25, 2001
Date of Patent:
June 3, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Application
Filed:
August 17, 2007
Publication date:
May 15, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Application
Filed:
August 17, 2007
Publication date:
April 24, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Darrell Anderson, Nabil Hanna, Peter Brams
Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
Type:
Grant
Filed:
August 5, 2002
Date of Patent:
March 4, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
Type:
Grant
Filed:
September 28, 2004
Date of Patent:
February 19, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Type:
Application
Filed:
August 11, 2006
Publication date:
February 14, 2008
Applicant:
Biogen Idec Inc.
Inventors:
Darrell R. Anderson, Nabil Hanna, Peter Brams